aTYR PHARMA INC(ATYR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

aTYR PHARMA INC (ATYR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATYR at 8.2/100 on a 32-signal composite quality model, placing it at rank #2,931 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), aTYR PHARMA INC reports net income of $-10.3M, free cash flow of $-9.4M. Top institutional holders of ATYR by reported 13-F value include FEDERATED HERMES, VANGUARD CAPITAL MANAGEMENT, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. ATYR trades on the Nasdaq exchange and files with the SEC under CIK 1339970. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATYR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for aTYR PHARMA INC directly from SEC EDGAR.

AI Quality Score

8.2/100

AI Rank

#2,931

Net Income

$-10.3M

Free Cash Flow

$-9.4M

ATYR key financials by period

aTYR PHARMA INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$190.0K$-74.1M—
FY 202410-K$235.0K$-64.0M—
FY 202310-K$353.0K$-50.4M—
FY 202210-K$10.4M$-45.3M—
FY 202010-K$10.5M$-16.2M-152.2%
FY 201910-K$422.0K$-16.2M—

Institutions holding ATYR

Institutional investors reporting a position in aTYR PHARMA INC on SEC Form 13F.
InstitutionSharesValueReported
FEDERATED HERMES8,509,678$5.1M2026-06-30
VANGUARD CAPITAL MANAGEMENT3,808,091$2.3M2026-06-30
GSA CAPITAL PARTNERS LLP3,454,863$2.1M2026-06-30
AQR CAPITAL MANAGEMENT2,610,548$1.6M2026-06-30
FMR2,471,418$1.5M2026-06-30
BlackRock1,827,332$1.1M2026-06-30
Kalehua Capital Management1,788,167$1.1M2026-06-30
JANE STREET GROUP1,721,297$1.0M2026-06-30
UBS Group AG1,531,151$914.1K2026-06-30
MORGAN STANLEY1,343,636$801.9K2026-06-30
SEC EDGAR: CIK 1339970 →
ATYR

aTYR PHARMA INC

ATYR
NasdaqSmall CapHealthcare

13F Pro Quality Score

8.2/100

Rank #2,931 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-10.31M

EPS (Diluted)

Q2 2026
EDGAR

$-0.11

Free Cash Flow

Q2 2026
EDGAR

$-9.42M

Top Institutional Holders

as of Q2 2026
$23.89M total
FEDERATED HERMES, INC.
$5.08M-19.0%
VANGUARD CAPITAL MANAGEMENT LLC
$2.27M-0.1%
GSA CAPITAL PARTNERS LLP
$2.06M+105.1%
AQR CAPITAL MANAGEMENT LLC
$1.56M+426.3%
FMR LLC
$1.47M-83.2%
BlackRock, Inc.
$1.09M-71.6%
Kalehua Capital Management LLC
$1.07MNew
JANE STREET GROUP, LLC
$1.03M+280.1%
UBS Group AG
$914.1K-60.4%
MORGAN STANLEY
$801.9K+9.6%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…